eprintid: 498
rev_number: 9
eprint_status: archive
userid: 30
dir: disk0/00/00/04/98
datestamp: 2022-01-17 11:17:29
lastmod: 2022-01-17 11:17:29
status_changed: 2022-01-17 11:17:29
type: thesis
metadata_visibility: show
creators_name: Adesanya, Omoniyi Sunday
corp_creators: Supervisor: Dr. Prosper Anaedu
title: Limitations Impacting Local Manufacturing of Vaccines: A Nigeria Case Study
ispublished: submitted
subjects: RS
divisions: MScPBT
full_text_status: public
abstract: Vaccination is an age long science that has been proven to prevent some deadly diseases, especially in children below the age of 5years. Therefore, it is empirical for any nation to stimulate the process of immunization and ensure that children and adults are protected from some of these infectious and deadly diseases. This will bring about a safe, healthy, and productive society where every individual within the system contributes their quota to the Gross Domestic Product (GDP) rather than treating the overall consequences of the lack of vaccination.This research work was initiated to critically consider the limitations that impact local manufacturing of vaccines in Nigeria. A review of various literature from articles, journals, workshop presentations at different scientific conferences and other sources on related topics, to see trends and events as it relates to effort made in local vaccines manufacturing. From the literature reviewed, it was evident that most of the vaccines production are from developed countries like china, India, Russia, Vietnam, United States of America, Europe with very few Africa countries currently manufacturing vaccines locally.In this research, qualitative method and Interpretivism philosophy of interviews arranged with experts on this subject matter were employed. Due to the prevailing pandemic ravaging the world, the researcher could not have a face-to-face interview with the identified experts contacted to be part of this research. Therefore, zoom meetings were set up and responses to the questions asked were all recorded and transcribed during the data analysis process. This process adequately ensured that the data collection process was effectively managed and with the use of thematic analysis, which is considered the most effective and preferred method used in qualitative data analysis based on its enormous benefits.From the data analyzed using the answers provided by the experts interviewed in this research work, some findings inferred. There is no vaccine currently manufactured locally in Nigeria. Advocacy could be considered a strong tool in achieving local manufacturing of vaccines. There are available government policies on local manufacturing of vaccines, but the problem majorly is the lack of policy implementation.Although the pharmaceutical industries are willing to engage in local manufacturing of vaccines. Also, the challenges facing the pharmaceutical industries in achieving local manufacturing of vaccines are numerous but could be upturned with government support. My researcher work has been able to identify some solution through the various recommendations and suggestions as discussed in chapter 5 of this dissertation. If these highlighted issues are implemented, then achieving local manufacturing of vaccines could be easily achieved and in good time.
date: 2021
date_type: completed
institution: Innopharma
department: Innopharma Education
thesis_type: masters
referencetext: ............................................................................................................................................... 48 APPENDICES ................................................................................................................................................ 50

Abdulkarim, A.A. et al. (2011) (4) ‘Vaccines and Immunization: The Past, Present and Future in Nigeria'. Nigerian Journal of Paediatrics, 38(4), pp. 186-194. DOI: 10.4314/njp.v38i4.72382.(Accessed 17 June 2021).

Africa Vaccine Manufacturing Initiative (2013) Session_8_tippoo.Pdf. Available at: https://www.who.int/influenza_vaccines_plan/resources/session_8_tippoo.pdf (Accessed: 20 July 2021).

BIOVACCINE NIG LTD (2017) BVNL-Company Profile. Available at: https://www.biovaccinesnig.com/companyprofile.php (Accessed: 24 May 2021).

Burney, M.I. (1993) ‘Transferring Manufacturing Technology. Producing Essential Vaccines in Pakistan'. International Journal of Technology Assessment in Health Care, 9(3), pp. 397- 406. DOI: 10.1017/s0266462300004657. (Accessed: 24 June 2021).

Elder, K. (2013) ‘Vaccine Prices: A Painful Shot for Africa'. OECD Observer, (296), pp. 29-29. (Accessed: 24 May 2021).

Friede, M. et al. (2011) ‘WHO Initiative to Increase Global and Equitable Access to Influenza Vaccine in the Event of a Pandemic: Supporting Developing Country Production Capacity through Technology Transfer'. Vaccine, 29, pp. A2-A7. DOI: 10.1016/j.vaccine.2011.02.079. (Accessed: 20 June 2021).

Hendriks, J., Liang, Y. and Zeng, B. (2010) ‘China's Emerging Vaccine Industry'. Human Vaccines, 6(7), pp. 602-607. DOI: 10.4161/hv.6.7.11933. (Accessed: 27 June 2021).

NAFDAC (2017) Vaccines & Biologics - NAFDAC. Available at: https://www.nafdac.gov.ng/2760 2/ (Accessed: 14 July 2021).

Nathan Ohiomokhare (2021) TECH FIRMS TO DELIVER COVID VACCINES IN AFRICA USING DRONES - CPAN WORLD. Available at: https://cpanworld.org.ng/2021/01/25/tech-firms-to-deliver covid-vaccines-in-africa-using-drones/ (Accessed: 10 July 2021).

Padmanabhan, S. et al. (2010) (7) ‘Intellectual Property, Technology Transfer and Manufacture of Low-Cost HPV Vaccines in India'. Nature Biotechnology, 28(7), pp. 671-678. DOI: 10.1038/nbt0710-671. (Accessed: 19 July 2021). Pagliusi, S., Hayman, B. and Jarrett, S. (2021) ‘Vaccines for a Healthy Future: 21st DCVMN Annual General Meeting 2020 Report'. Vaccine, 39(18), pp. 2479-2488. DOI: 10.1016/j.vaccine.2021.03.025. (Accessed: 24 June 2021).

Rey-Jurado, E. et al. (2018) ‘Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution'. Frontiers in Immunology, 9, p. 26. DOI: 10.3389/fimmu.2018.00026. (Accessed: 10 July 2021).

Ronald A. Rader and Eric S. Langer. (2014) Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries. BioProcess International. Available at: https://bioprocessintl.com/manufacturing/monoclonal-antibodies/bioprocess-advances drive-vaccine-manufacturing-in-developing-countries-349767/ (Accessed: 9 May 2021).

Saunders, M., Lewis, P. and Thornhill, A. (2009) Research Methods for Business Students. Harlow: Financial Times Prentice Hall. (Accessed: 29 June 2021).

TOYIN ABIODUN, HAYLEY ANDERSEN, and LIYA TEMESELEW MAMO, OB SISAY (2021) Vaccine Manufacturing in Africa: What It Takes and Why It Matters. Institute for Global Change. Available at: https://institute.global/advisory/vaccine-manufacturing-africa-what-it-takes and-why-it-matters (Accessed: 14 June 2021).

WHO (2021a) Vaccines and Immunization. Available at: https://www.who.int/westernpacific/health-topics/vaccines-and-immunization (Accessed: 5 June 2021).

WHO (2021b) What Is Africa's Vaccine Production Capacity? WHO | Regional Office for Africa. Available at: https://www.afro.who.int/news/what-africas-vaccine-production-capacity (Accessed: 24 May 2021).

WHO (2016) WHO-HIS-TTi-17.2-Eng.Pdf. Available at: https://apps.who.int/iris/bitstream/handle/10665/254184/WHO-HIS-TTi-17.2-eng.pdf (Accessed: 9 May 2021).

Zoltán Kis, Robin Shattock, Nilay Shah, Cleo Kontoravdi (2018) Emerging Technologies for Low‐ Cost, Rapid Vaccine Manufacture - Kis - 2019 - Biotechnology Journal - Wiley Online Library. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/biot.201800376 (Accessed: 9 June 2021). APPENDICES
citation:   Adesanya, Omoniyi Sunday  (2021) Limitations Impacting Local Manufacturing of Vaccines: A Nigeria Case Study.  Masters thesis, Innopharma.   
document_url: http://go.griffith.ie/498/1/15624_Omoniyi_Sunday_Adesanya_COMPLETE_DISSERTATION_153335_2119230957.pdf
document_url: http://go.griffith.ie/498/2/bibliography.txt